PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2963592-7 1988 Moreover, the monoamine oxidase B inhibitor, pargyline, prevented the rise in cytosolic free Ca2+ concentration and partially protected the plasma membrane Ca2+-ATPase from inhibition by MPTP. Pargyline 45-54 monoamine oxidase B Homo sapiens 14-33 3566791-8 1987 With the same digestion and separation procedures, only one major radioactive peak was observed for the [3H]pargyline-labeled MAO-B, and its elution volume was different from that of [3H]FNPA-labeled peptides. Pargyline 108-117 monoamine oxidase B Homo sapiens 126-131 3566791-9 1987 These results suggest that, upon photolysis, FNPA may incorporate into a region in the active site of MAO-B which may be different from the pargyline binding site--the FAD prosthetic group of the enzyme. Pargyline 140-149 monoamine oxidase B Homo sapiens 102-107 20501066-6 1987 They could be protected by the presence of the substrate (phenylethylamine) or inhibitors (pargyline and trans-phenylcyclopropylamine) of MAO-B during photolysis. Pargyline 91-100 monoamine oxidase B Homo sapiens 138-143 3527152-3 1986 The antibody indirectly precipitates [3H]pargyline-labelled human MAO B both from liver and platelet extracts but fails to precipitate MAO A from liver extracts. Pargyline 41-50 monoamine oxidase B Homo sapiens 66-71 6335034-2 1984 MPTP is oxidized by brain mitochondrial preparations in a process which is blocked by deprenyl and pargyline, implying catalysis by monoamine oxidase B. Pargyline 99-108 monoamine oxidase B Homo sapiens 132-151 3011983-7 1986 Monoamine oxidase inhibitors such as deprenyl, pargyline and harmaline have affinities to the MPTP receptors which parallel their affinity for the B type of monoamine oxidase (MAO B). Pargyline 47-56 monoamine oxidase B Homo sapiens 176-181 6359210-4 1983 Pargyline inhibits monoamine oxidase, type B, and its therapeutic efficacy is compatible with the hypothesis that decreased phenethylaminergic function, dopaminergic function, or both play a role in the etiology of the disorder. Pargyline 0-9 monoamine oxidase B Homo sapiens 19-44 111275-2 1979 During a similar 4-week crossover treatment period with pargyline, a selective MAO-B inhibitor, platelet MAO activity was essentially completely inhibited in the same individuals. Pargyline 56-65 monoamine oxidase B Homo sapiens 79-84 6191193-4 1983 The concentration of immunologically detectable MAO B protein in the extracts was estimated from immunoprecipitation competition data by reference to a standard curve relating observed inhibition of immunoprecipitation to the concentration of catalytically active platelet MAO added (estimated from [3H]pargyline binding data). Pargyline 303-312 monoamine oxidase B Homo sapiens 48-53 6822482-2 1983 The pharmacologic actions of pargyline are discussed with regard to its partial selectivity for MAO-B and presumed action in dopamine systems, and clinicians are alerted to this uncommon drug reaction. Pargyline 29-38 monoamine oxidase B Homo sapiens 96-101 7264664-2 1981 [3H]Pargyline was bound to MAO A in a crude mitochondrial fraction from the placental trophoblast of a male newborn and to MAO B in blood platelets from the umbilical vein of the same newborn. Pargyline 4-13 monoamine oxidase B Homo sapiens 123-128 6791210-5 1981 Chronic treatment with the MAO-A inhibitor clorgyline and the MAO-B inhibitor pargyline showed significant inhibition of the alternate MAO enzyme as well, although this crossover effect was greater for pargyline than clorgyline. Pargyline 78-87 monoamine oxidase B Homo sapiens 62-67 6791210-5 1981 Chronic treatment with the MAO-A inhibitor clorgyline and the MAO-B inhibitor pargyline showed significant inhibition of the alternate MAO enzyme as well, although this crossover effect was greater for pargyline than clorgyline. Pargyline 202-211 monoamine oxidase B Homo sapiens 62-67 28685208-5 2017 In addition, iron-induced increase in MAO-B probe fluorescence could be prevented by pargyline and other newly developed MAO-B inhibitors, suggesting that it was MAO-B activity-dependent. Pargyline 85-94 monoamine oxidase B Homo sapiens 38-43 9564606-0 1998 Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). Pargyline 131-140 monoamine oxidase B Homo sapiens 109-114 23499958-6 2013 The inhibition of both MAO-A and MAO-B by clorgyline and pargyline, respectively, enhanced the effects of cocaine on DARPP-32 phosphorylation. Pargyline 57-66 monoamine oxidase B Homo sapiens 33-38 21341713-1 2011 TEMPO-substituted pargyline analogues differentially inhibit recombinant human monoamine oxidase A (MAO A) and B (MAO B) in intact yeast mitochondria, suggesting these membrane-bound enzymes are located on differing faces of the mitochondrial outer membrane [Upadhyay, A., and Edmondson, D. E. (2009) Biochemistry 48, 3928]. Pargyline 18-27 monoamine oxidase B Homo sapiens 114-119 17030739-2 2006 The 3A resolution structure of recombinant human MAO-B originally determined was of the enzyme complexed with pargyline, an irreversible inhibitor covalently bound to the N5 atom of the flavin coenzyme. Pargyline 110-119 monoamine oxidase B Homo sapiens 49-54 12777388-7 2003 Cys5 and Cys266 were identified as the only residues modified by biotin-derivatized NEM in clorgyline-inactivated MAO A and pargyline-inactivated MAO B, respectively. Pargyline 124-133 monoamine oxidase B Homo sapiens 146-151 12777388-15 2003 This study shows that the MAO A structure is "more flexible" than that of MAO B and that clorgyline and pargyline inactivation of MAO A and B, respectively, increases the structural stability of both enzymes. Pargyline 104-113 monoamine oxidase B Homo sapiens 74-79 11753429-4 2002 The electron density shows that pargyline, an analog of the clinically used MAO B inhibitor, deprenyl, binds covalently to the flavin N5 atom. Pargyline 32-41 monoamine oxidase B Homo sapiens 76-81 26263056-7 2015 The developed method was successfully applied for detection of the MAO-A and MAO-B inhibitive activities by model drugs, including pargyline, clorgyline, as well as beta-carboline alkaloids from Peganum harmala. Pargyline 131-140 monoamine oxidase B Homo sapiens 77-82 19789505-3 2009 MATERIAL/METHODS: We investigated MAO labeling with mechanism-based inhibitor [3H]pargyline activities of MAO A, MAO B, and SSAO in healthy and inflamed human dental pulp. Pargyline 82-91 monoamine oxidase B Homo sapiens 113-118 15279562-4 2004 The recent development of high level expression systems for producing recombinant human liver MAO A and MAO B in Pichia pastoris has facilitated the determination of the three dimensional crystal structures of MAO B (up to 1.7 angstroms resolution) in complex with different reversible (isatin, 1,4-diphenyl-2-butene) and irreversible inhibitors (pargyline, N-(2-aminoethyl)-p-chlorobenzamide, and trans-2-phenylcyclopropylamine). Pargyline 347-356 monoamine oxidase B Homo sapiens 210-215 9564606-2 1998 In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B > MAO-A inhibitor used in doses of 90 mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied. Pargyline 86-95 monoamine oxidase B Homo sapiens 100-105 7953696-9 1994 Administration of deprenyl or pargyline, together with pCA, itself a MAO-A inhibitor, will lead to inhibition of both MAO-A and MAO-B activities. Pargyline 30-39 monoamine oxidase B Homo sapiens 128-133 9503561-4 1997 MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline. Pargyline 251-260 monoamine oxidase B Homo sapiens 110-115 1413647-7 1992 Possible biological significance of alterations in the amine oxidases ratio in the growing placenta is discussed considering the known property of the MAO-B inhibitor pargyline to cause abortion within early periods of pregnancy. Pargyline 167-176 monoamine oxidase B Homo sapiens 151-156 2111588-7 1990 Selective accumulation of [125I]MHTP-derived radioactivity within these structures was blocked by pretreatment with pargyline, suggesting that monoamine oxidase B is involved in the bioactivation of radioiodinated MHTP. Pargyline 116-125 monoamine oxidase B Homo sapiens 143-162 1686901-0 1991 Synthesis, biological evaluation and quantitative structure activity relationship analysis of nuclear-substituted pargylines as competitive inhibitors of MAO-A and MAO-B. Pargyline 114-124 monoamine oxidase B Homo sapiens 164-169 34641548-2 2021 Compounds NEA3 and NEA1 exhibited a more potent MAO-B inhibition (IC50 value = 0.0092 and 0.016 microM, respectively) than the standards (IC50 value = 0.11 and 0.14 microM, respectively, for lazabemide and pargyline). Pargyline 206-215 monoamine oxidase B Homo sapiens 48-53